Lakewood-Amedex Redeems All Series C Preferred for $1.27M

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) said on November 5, 2026 that it completed the redemption of all 127,097 remaining outstanding shares of its Series C Convertible Preferred Stock, paying an aggregate cash redemption price of $1,270,970 from cash on hand under a redemption agreement dated November 2, 2026 with Shakawe Capital LLC. The company said no Series C shares remain outstanding, no common stock is issuable on their conversion, and it now carries no preferred stock and no outstanding indebtedness for borrowed money.

Context — Why a $1.27M Preferred Redemption Matters for LABT

The redemption price works out to $10.00 per Series C share, a figure derived from the two numbers the company disclosed: $1,270,970 divided by 127,097 shares. That implied per-share value is the only pricing reference the report gives, and the company did not disclose the original issuance terms, liquidation preference, dividend rate or conversion ratio attached to the instrument.

The report also gives no comparison to a prior period, no earlier redemption tranche, and no timeline for when the Series C was originally issued. What the company does say is that the transaction was the final step: this was the remaining balance, not a partial buyback, so the capital structure change is complete rather than staged.

That distinction matters because convertible preferred stock sits between debt and common equity in a biotech capital stack. Each outstanding preferred share carries a conversion right into common stock, and every conversion adds to the share count. By retiring the instrument, the company removes that future issuance channel entirely.

Kelvin Cooper, Ph.D., the company's Chief Executive Officer, framed the move around two effects. The redemption "simplifies our capital structure and eliminates the potential for further dilution from conversion of the Series C Preferred Stock," he said, adding that it removes the financing restrictions tied to the instrument and gives the company "greater financial flexibility" as it advances its development programs.

The macro backdrop is not supplied by the report. No interest rate, index level or sector benchmark is cited, so the transaction stands on its own terms as a balance-sheet event rather than a rate-sensitive one.

Data — What the LABT Redemption Numbers Show

The disclosed figures are narrow and specific. The company redeemed 127,097 shares for $1,270,970 in cash, funded from cash on hand rather than from new borrowing or an equity raise. The implied price per share is $10.00.

Before and after the transaction, the preferred equity line changed as follows: 127,097 Series C shares outstanding became zero, and the company's preferred stock balance moved from one class outstanding to none. The company also stated that outstanding indebtedness for borrowed money moved to zero.

The report does not give the company's total cash balance before or after the payment, its cash runway, its quarterly burn rate, or its total share count. Without those inputs, the $1,270,970 outlay cannot be expressed as a percentage of cash reserves or as a number of months of operating expenses.

No peer comparison is available either. The report names no comparable biotech redemption, no sector aggregate, and no index against which to benchmark the transaction. What can be said is that the redemption was small in absolute dollar terms for a NASDAQ-listed clinical-stage company, and that it was settled in cash rather than stock.

The company's pipeline description is the other concrete item in the report: Lakewood-Amedex is developing the Bisphosphocin class of fast-acting, broad-spectrum antimicrobials aimed at infectious diseases and antibiotic-resistant strains including MRSA and VRE. The report gives no trial phase, enrollment figure, endpoint or regulatory milestone date for any program.

Analysis — Dilution Removal, Liquidity Cost and Who Is Exposed

The clearest second-order effect runs through the share count. Convertible preferred stock is a latent supply of common shares. Removing it removes the mechanical path by which the float could grow through conversion, which is the outcome the CEO pointed to. For holders of LABT common stock, that eliminates one source of future dilution without requiring a shareholder vote or a new agreement.

The offsetting effect sits on the asset side of the balance sheet. The company paid $1,270,970 in cash. The report does not quantify the resulting cash position, so the trade-off between reduced dilution and reduced liquidity cannot be sized from the disclosure alone. The company's own risk language acknowledges this directly, flagging that "the use of cash to fund the redemption may reduce the Company's liquidity and cash runway."

The counter-argument is straightforward: a clinical-stage biotech that spends cash to retire a small preferred position is trading optionality on its balance sheet for a cleaner cap table. If the company needs to raise again, it will do so from a structure with no preferred overhang and no instrument-specific financing restrictions, which the CEO said were removed. Whether that improves terms is not something the report establishes.

Positioning is not disclosed. The report gives no holder data, no short interest, no institutional ownership and no trading volume. Shakawe Capital LLC is named as the counterparty to the redemption agreement, and the report does not describe the firm's remaining relationship with the company or whether it holds any other securities.

Sector exposure is similarly unspecified. The report names no peers, no index membership and no read-through to other antimicrobial developers, so any claim that the transaction signals something about the broader antibiotics space would go beyond what the company disclosed.

Outlook — What to Watch After the Series C Redemption

The report names no upcoming catalysts, no trial readout dates, no regulatory submission windows and no financing plans. That absence is itself the key item: the company said the redemption gives it "greater financial flexibility," but did not say what that flexibility will be used for.

Three things a reader can track from the disclosure. First, whether the company reports a materially lower cash balance in its next quarterly filing, since the redemption was funded from cash on hand. Second, whether the removal of the Series C financing restrictions is followed by a new financing agreement, and on what terms. Third, whether the company provides any program-level update on the Bisphosphocin candidates, none of which carries a disclosed timeline in this report.

No price levels, moving averages or yield thresholds are given in the report, and none can be attached to this transaction from the disclosure. The company's forward-looking statement section lists the relevant uncertainties: benefits of the redemption may not be realized, liquidity and cash runway may be reduced, and additional financing may not be available on acceptable terms or at all.

Frequently Asked Questions

What does the Lakewood-Amedex Series C redemption mean for retail investors?

It removes a known source of future dilution. Each Series C share carried a right to convert into common stock, and all 127,097 shares are now retired, so no additional common shares will be issued on that conversion. The trade-off is that the company spent $1,270,970 of cash on hand to do it, and the report does not disclose the remaining cash balance.

What happens next for LABT's capital structure?

The company said it now has no preferred stock outstanding and no outstanding indebtedness for borrowed money. That leaves common equity as the only disclosed equity class. The report gives no information on whether the company plans to raise capital, issue new instruments, or pursue any specific financing, and it names no timeline for a next transaction.